Withdrawn study sought better way to time eye injections

NCT ID NCT03435926

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if how well a person can fix their gaze relates to signs of active disease on eye scans in patients with age-related macular degeneration (ARMD) treated with antiVEGF injections. Researchers planned to follow patients for two years, measuring fixation quality and scan results at each visit. The goal was to improve when to give repeat injections. However, the study was withdrawn before any participants were enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If a link is found, it could help doctors decide when to retreat ARMD patients more precisely, potentially improving treatment timing.

What could go wrong

The study was withdrawn before enrolling anyone, so no results are available. It is unclear if the approach would work in practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

choroidal neovascularization wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospital

    Limoges, 87042, France